Brukinsa (zanubrutinib) is a small molecule pharmaceutical. Zanubrutinib was first approved as Brukinsa on 2019-11-14. It is used to treat mantle-cell lymphoma in the USA. It is known to target tyrosine-protein kinase BTK. Brukinsa's patents are valid until 2037-08-15 (FDA).
|Drug Class||Tyrosine kinase inhibitors: Bruton's (Btk) inhibitors|